Digital Pathology Focuses on Forward Push Amid Regulatory Uncertainty

| October 7, 2010

Digital pathology continues to generate industry buzz, especially with numerous heavy hitters like Aperio, Olympus, and Bioimagene displaying a significant presence at this week’s CAP ’10 meeting. Standardization is also moving forward with the recent release of the medical image exchange standard Supplement 145 from The Digital Imaging and Communications in Medicine (DICOM) Standards Committee, of which the CAP is a member.

However, while there are over a dozen FDA 510(k) clearances for digital analysis of immunohistochemistry procedures, the waiting game continues for how the agency wants to regulate digitalization of hematoxylin and eosin (H&E) slides using whole slide imagng (WSI) systems, according to Steve Potts, PhD, CEO of digital pathology service provider Flagship Biosciences (Flagstaff, AZ). Potts recently spoke at a histology image analysis webinar on regulation and digital pathology hosted by Denver-based Digital Pathology Consultants.

There has been no word from the FDA since October 2009, when stakeholders—including the CAP and digital pathology companies—testified before the agency’s Hematology and Pathology Devices Advisory Committee during a public comment period to address oversight of whole slide imagining (WSI) systems.

One key issue is whether these systems should be subjected to the agency’s Class II or Class III requirements. While Class II products are frequently “cleared” by the 510(k) process, Class III devices must go through the PMA process. This process requires more investment—both in money and time—as the device has to be “approved” as safe and effective after undergoing clinical trials. The CAP testified at the hearing, primarily on recommendations for validating WSI systems.

Dr. Potts speculates that WSI will likely be considered Class II devices and will need to be cleared by the FDA. He added that subsequent pathology procedures using this device will then be considered laboratory developed tests (LDTs), as the regulatory filings will likely be for specific applications. However, this could further delay momentum, as the FDA is currently crafting LDT oversight framework.

Nevertheless, Dr. Potts believes that once these regulatory barriers are negotiated, digital pathology will move ahead at breakneck speed. “When this technology starts to move into labs and pathology practices, it will come fast,” he predicted.


Category: Digital Pathology News, Histology, Pathology News

Comments (3)

Trackback URL | Comments RSS Feed

  1. Karl Robstad says:

    Two questions:
    1. Do you think WSI should require FDA approval? Obviously oversight and regulation are required in medicine for patient safety, but the FDA doesn’t have to approve every new Olympus BX-## that comes out, right?
    2. Do you think legislation (or the lack thereof) is hampering innovation in this case (WSI or IHC scoring)?

  2. Steve Potts says:

    Good questions, Karl. My own opinion, and of course that is all it is, is that WSI viewing aspects should not require FDA approval. There is no precedent for approving any microscope for use by the pathologist in viewing slides. Image analysis is a different story. If there is an approval required for WSI, it should focus on whether the WSI device delivers the same or better optics as a microscope, not how a pathologist diagnoses using a WSI device. Very important distinction

  3. Bloomington MN hotel – A French-inspired full service hotel located in the heart of Minneapolis and Bloomington, Minnesota—minutes from Minneapolis-St. Paul International Airport (MSP) and Mall of America. Features include, pillow top mattresses, flat screen LCD TV’s, L’Occitane bath amenities, fitness center, indoor heated pool, business center, café espresso bar, bistro and lobby bar
    Cat boarding.